ACM
TEVA icon

Accipiter Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Accipiter Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-100,000
Closed -$2.43M – 7
2018
Q2 		$2.43M Sell
100,000
-47,571
-32% -$970K 0.79% 7
2018
Q1 		$2.52M Sell
147,571
-276,493
-65% -$5.4M 5.32% 4
2017
Q4 		$8.04M Sell
424,064
-180,121
-30% -$2.71M 16.34% 2
2017
Q3 		$10.6M Buy
604,185
+402,040
+199% +$9.05M 21.87% 2
2017
Q2 		$6.71M Buy
202,145
+2,145
+1% +$66.4K 14.02% 2
2017
Q1 		$6.42M Sell
200,000
-4,030
-2% -$138K 10.99% 2
2016
Q4 		$7.4M Buy
204,030
+28,117
+16% +$1.12M 5.88% 6
2016
Q3 		$8.09M Buy
175,913
+1,290
+0.7% +$67.3K 3.92% 7
2016
Q2 		$8.77M Sell
174,623
-24,817
-12% -$1.32M 7.17% 6
2016
Q1 		$10.7M Buy
199,440
+66,652
+50% +$3.91M 6.1% 5
2015
Q4 		$8.72M Buy
+132,788
New +$8.21M 4.76% 11
2014
Q3 		$4.46M Sell
83,035
-163
-0.2% -$8.64K 8% 8
2014
Q2 		$4.36M Buy
83,198
+16,840
+25% +$861K 8.06% 6
2014
Q1 		$3.51M Sell
66,358
-282,436
-81% -$13.1M 7.96% 5
2013
Q4 		$14M Sell
348,794
-89,378
-20% -$3.52M 17.81% 3
2013
Q3 		$16.6M Buy
438,172
+75,404
+21% +$2.94M 15.21% 2
2013
Q2 		$14.2M Buy
+362,768
New +$14.1M 11.16% 4

Other funds holding TEVA

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Berkshire Hathaway
Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
HCM
Highfields Capital Management Boston, Massachusetts $68.3M AUM 21.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Accipiter Capital Management's TEVA Position: Q3 2018 in Review

Accipiter Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q3 2018, closing a stake of 100,000 shares — an estimated $2.43M sold.

Accipiter Capital Management first reported a position in TEVA in Q2 2013 and held it in 17 quarters. The position peaked at $16.6M in Q3 2013. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2018.

  • Accipiter Capital Management reported no remaining Teva Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Accipiter Capital Management sold 100,000 Teva Pharmaceuticals shares in Q3 2018, an estimated $2.43M.
  • Accipiter Capital Management first reported a position in Teva Pharmaceuticals in Q2 2013 and held it in 17 quarters.
  • Accipiter Capital Management's Teva Pharmaceuticals position peaked at $16.6M in Q3 2013.
  • 557 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q3 2018.

Based on Accipiter Capital Management's 13F filing for Q3 2018, filed 14 Nov 2018.